About

Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain. The Company’s lead candidate, MTX110, is being studied in aggressive rare/orphan brain cancer indications including recurrent glioblastoma, medulloblastoma and paediatric diffuse midline glioma.

MTX110 is a solubilised formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at chemotherapeutic doses directly to the site of the tumour, by-passing the blood-brain barrier and potentially avoiding systemic toxicity.

Our Mission

Our mission is to advance medicines that will provide a brighter future for patients with serious conditions that are not fully served by existing treatments.

Leadership

Core to Biodexa Pharmaceuticals strength is its highly experienced and dedicated team.

The Biodexa Pharmaceuticals team benefits from cross-functional expertise including formulation science and pharmaceutical development. With over 10 years’ experience of working together the team has translated multiple programmes from concept to clinic across three distinct technology platforms and apply extensive knowledge and expertise to deliver rapid R&D innovation and value creation.

Stephen Stamp

CEO / CFO

Dmitry Zamoryakhin

Chief Scientific Officer

Dan Palmer

VP Technology

Fiona Sharp

Group Financial Controller

Steve Ellul

VP Business Development

Nicola Tuckwell

VP Head of Clinical Operations

Board of Directors

Stephen Parker

Non-executive Chairman

Stephen Stamp

CEO / CFO

Simon Turton

Senior Independent Non-executive Director

Sijmen de Vries

Non-executive Director

Stephen Stamp

CEO / CFO

Mr. Stamp is an experienced public company CFO and has held senior positions in a number of significant healthcare companies including as Group Finance Director of Shire plc, Chief Operating Officer of Xanodyne Pharmaceuticals Inc and most recently with AIM quoted Ergomed plc, where he served initially as CFO before becoming CEO. Mr Stamp qualified as a Chartered Accountant at KPMG and is a member of the Institute of Chartered Accountants.

Dmitry Zamoryakhin

Chief Scientific Officer

Dmitry has joined the company in 2021 as a Chief Scientific Officer and is responsible for all R&D activities of Biodexa Pharmaceuticals. He is a medically trained professional with over 17 years of experience in drug and medical devices development.

Prior to joining Biodexa Pharmaceuticals, Dmitry served as a Chief Medical Officer at Oxford Biomedica plc, a company specialising in development products within the cell & gene area. He has also had roles of increasing responsibilities within GSK, Ono Pharma, Daiichi Sankyo and Grunenthal.

Dmitry holds a MD from the Perm State Medical Academy (Russia), a MBA from the Warwick University and a diploma in pharmaceutical medicine from the Universite Libre de Bruxelles.

Dan Palmer

VP Technology

Dan has 17 years experience in the biotech sector with particular focus on drug delivery and nanotechnologies for oncology. He has managed interdisciplinary R&D programmes across biology, chemistry and engineering. As well as leading Biodexa Pharmaceuticals’ exploratory oncology R&D, Dan is responsible for management of Biodexa Pharmaceuticals' intellectual property portfolio.

Dan holds a PhD in Chemistry, an MBA from Imperial College Business School and is a Fellow of the Royal Society of Chemistry.

Fiona Sharp

Group Financial Controller

Fiona is a qualified accountant and has held senior finance positions within the PR and advertising industry, including Group Finance Director of Chime Communications Group. Fiona is a Fellow of the Chartered Association of Certified Accountants.

Steve Ellul

VP Business Development

A chemist by training, Steve has spent more than 30 years in commercially focused roles across multiple sectors of the pharmaceutical industry. Steve has led commercial teams at drug delivery organisations, including Eurand and Bespak, and has held senior roles at speciality pharma companies, Elan, Shire and Theravance Biopharma.

Nicola Tuckwell

VP Head of Clinical Operations

Nicola has over 30 years’ global clinical development experience covering all phases in a broad range of therapeutic areas, as well as more specialist cell and gene therapies and medical device development. Prior to joining Biodexa Pharmaceuticals, she has held senior positions in companies such as Oxford Biomedica, Takeda, Ark Therapeutics, Silence Therapeutics (formerly SR Pharma) and Cephalon. Nicola studied Biochemistry and holds a MSc in Pharmacology.

Simon Parker

Non Executive Chairman

Stephen Parker has over 30 years’ experience in leadership roles both in the healthcare industry and in advisory roles. Currently, he is Chairman of Sareum Holdings plc (AIM: SAR) and Drishti Discoveries Ltd., a Non-Executive Director of MGC Pharmaceuticals Ltd (ASX,LSE: MXC) and an Executive Director of sp2 Consulting Limited. Previously, Stephen held a number of executive and board positions at various public and private biotech companies and senior roles at leading investment banks. Stephen has an MBA from City University and a D.Phil. in biochemistry from Oxford University.

Simon Turton

Senior Independent Non-executive Director

Dr Turton previously headed Warburg Pincus’ healthcare investing activities in Europe and was a principal at Index Ventures in Geneva. He has over 10 years of experience investing in biopharma companies following a ten-year career in the international pharmaceutical industry incorporating roles in research, business development and general management. Dr Turton has an MBA from INSEAD and a Ph.D. in pharmacy from the University of London. He has been a board director of private and public biomedical companies: Archimedes Pharma, Eurand, ProStrakan and Tornier. Dr Turton was most recently chairman of Q Chip prior to its acquisition by the Group. He is currently CEO of Gensmile, a new dental corporate building a group of dental clinics in the UK.

Sijmen de Vries

Non-executive Director

Dr de Vries has extensive senior level experience in both the pharmaceutical and biotechnology industry. He is currently CEO and CFO of Pharming group N.V., the Euronext-listed pharmaceutical company. Dr de Vries was previously CEO of both Switzerland-based 4-Antibody and Morphochem AG, and prior to this he worked at Novartis Pharma, Novartis Ophthalmics and at SmithKline Beecham Pharmaceuticals Plc, where he held senior business and commercial positions. Dr de Vries holds an MD degree from the University of Amsterdam and a MBA in General Management from Ashridge Management College (UK).